A major advance in the treatment of renal cell carcinoma (RCC) over the last few years has been the introduction into clinical practice of antitumor agents that function primarily as inhibitors of vascular endothelial growth factor (VEGF)-driven angiogenesis. The gene discussed is VEGFA; the disease is renal cell carcinoma.